VEGF neutralizing prodrugs for the treatment of ocular conditions

US10519226B2 · kind B2 · utility

Assignee

• Ascendis Pharma Opthalmology Division A/S · DK

Inventors

• Harald Rau · Würzburg, DE
• Thomas Knappe · Heidelberg, DE
• Burkhardt Laufer · Birkenfeld, DE
• Romy Reimann · Heidelberg, DE
• Samuel Weisbrod · Heidelberg, DE
• Kennett Sprogøe · Rudegård, DK
• Nicola Bisek · Heidelberg, DE
• Sebastian Stark · Heidelberg, DE
• Tobias Voigt · Heidelberg, DE

Key dates

• Filing date: Oct 8, 2013
• Grant date: Dec 31, 2019
• Expiry date: Oct 8, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/90
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to a pharmaceutical composition comprising one or more pharmaceutically acceptable excipient(s) and a VEGF neutralizing prodrug, which comprises a VEGF neutralizing biologically active moiety, for use in a method for the treatment of one or more ocular conditions.